한양대학교병원은 서울특별시 성동구에 위치한 상급종합병원이다.

During the past decade, Hanyang University Seoul Hospital conducted 124 clinical trials. In the 10-year time frame, 124 clinical trials started and 25 clinical trials were completed, i.e. on average, 20.2% percent of trials that started reached the finish line to date. In the past 5 years, 53 clinical trials started and 18 clinical trials were completed. i.e. 34% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hanyang University Seoul Hospital" #1 sponsor was "Pfizer" with 12 trials, followed by "Hanyang University" with 10 trials sponsored, "Hanyang University Seoul Hospital" with 10 trials sponsored, "Eli Lilly and Company" with 9 trials sponsored and "Seoul National University Hospital" with 9 trials sponsored. Other sponsors include 108 different institutions and companies that sponsored additional 83 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hanyang University Seoul Hospital" #1 collaborator was "Hanyang University" with 10 trials as a collaborator, "Samsung Medical Center" with 4 trials as a collaborator, "Severance Hospital" with 4 trials as a collaborator, "CardioVascular Research Foundation, Korea" with 3 trials as a collaborator and "Chung-Ang University Hosptial, Chung-Ang University College of Medicine" with 3 trials as a collaborator. Other collaborators include 103 different institutions and companies that were collaborators in the rest 82 trials.

According to Clinical.Site data, the most researched conditions in "Hanyang University Seoul Hospital" are "Rheumatoid Arthritis" (13 trials), "Amyotrophic Lateral Sclerosis" (6 trials), "Cardiac Arrest" (5 trials), "Alzheimer's Disease" (4 trials) and "Osteoarthritis" (4 trials). Many other conditions were trialed in "Hanyang University Seoul Hospital" in a lesser frequency.

Most popular intervention types in "Hanyang University Seoul Hospital" are "Drug" (103 trials), "Biological" (26 trials), "Device" (18 trials), "Other" (15 trials) and "Procedure" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (42 trials), "Baricitinib" (3 trials), "Infliximab" (3 trials), "Atezolizumab" (2 trials) and "CKD-495 75mg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hanyang University Seoul Hospital" are 155 trials for "All" genders, 4 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Hanyang University Seoul Hospital". undefined are not yet recruiting, 23 are recruiting, 11 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 89 completed trials in Hanyang University Seoul Hospital, undefined suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in Hanyang University Seoul Hospital, 9 "Phase 1" clinical trials were conducted, 28 "Phase 2" clinical trials and 58 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 21 trials, and there were also 21 trials that are defined as “Not Applicable".

Hanyang University Seoul Hospital has several departments that took part in Clinical trials: "Hanyang University Hospital, Department of Rheumatology" - 5 trials, "Hanyang university guri hospital, Department of emergency medicine" - 4 trials, "Department of Orthopaedic Surgery, Hanyang University, College of Medicine" - 3 trials, "Hanyang University Seoul Hospital, Cell Therapy Center for Neurologic Disorders" - 2 trials